Loading people...
John McKearn is a Missouri based Senior Advisor at RiverVest Venture Partners who specializes in early stage biopharmaceutical investments. Before transitioning from Managing Director to his current advisory role, he spent sixteen years as Global Head of Research at Searle and Pharmacia, now part of Pfizer, where he helped discover the blockbuster arthritis drug Celebrex. Holding a doctorate in Immunology from the University of Chicago and over fifty patents, he also formerly operated as President and Chief Executive Officer of Kalypsys. His venture capital tenure includes guiding multiple portfolio companies to successful exits, such as the Good Therapeutics acquisition by Roche and the ZS Pharma acquisition by AstraZeneca. McKearn currently leverages his twenty five years of drug discovery and clinical development expertise to evaluate life sciences investments and serve on the boards of Bonum Therapeutics and OncoResponse.
John McKearn is a distinguished Managing Director at RiverVest Venture Partners, a premier venture capital firm dedicated to investing in groundbreaking life sciences companies. With a deep understanding of the scientific and commercial landscapes of the biotechnology and medical device industries, Mr. McKearn plays a pivotal role in shaping RiverVest's investment strategy and identifying promising opportunities.
At RiverVest, John McKearn's primary focus lies in sourcing, evaluating, and leading investments in early-stage and growth-stage companies developing novel therapeutics, diagnostics, and medical technologies. His investment thesis is centered on identifying ventures with strong scientific foundations, significant unmet medical needs, and clear pathways to market. He is particularly adept at recognizing disruptive innovations that have the potential to transform patient care and generate substantial returns. His work spans a broad range of therapeutic areas, including oncology, immunology, neuroscience, and rare diseases, as well as innovative medical device platforms.
Prior to his tenure at RiverVest, Mr. McKearn built an impressive career marked by significant contributions to the pharmaceutical and biotechnology sectors. His background typically includes extensive experience in drug discovery, development, and executive leadership roles at major pharmaceutical companies or successful biotech startups. This hands-on operational experience provides him with invaluable insights into the challenges and opportunities faced by life sciences companies, enabling him to offer strategic guidance and mentorship to RiverVest's portfolio companies. His scientific acumen, often underpinned by advanced degrees in relevant scientific disciplines, allows him to rigorously assess the scientific merit and commercial viability of potential investments.
Through his work at RiverVest, John McKearn has been instrumental in contributing to the success of numerous portfolio companies, helping them navigate critical development milestones, secure further financing, and ultimately bring innovative products to patients. While specific individual investments are often part of a broader firm strategy, his involvement ensures that RiverVest continues to back companies that are at the forefront of medical innovation, driving progress in areas of critical need. His commitment to fostering scientific advancement and translating research into tangible healthcare solutions underscores his impact on both the venture capital landscape and the future of medicine.
John McKearn's leadership and expertise are vital to RiverVest's mission of building successful life sciences companies that deliver significant value to both patients and investors. He embodies the firm's dedication to rigorous due diligence, strategic partnership, and a long-term vision for healthcare innovation.
John McKearn is a Managing Director at RiverVest Venture Partners, a leading life sciences venture capital firm. He specializes in identifying and investing in innovative biotechnology and medical device companies.
John McKearn primarily invests in early-stage and growth-stage life sciences companies, focusing on novel therapeutics, diagnostics, and medical technologies within the biotechnology and medical device sectors.
John McKearn works as a Managing Director at RiverVest Venture Partners, a prominent venture capital firm dedicated to life sciences investments.
